All In Biotech

Drug Trial Radar · NCT07714447

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer: a Multicentre, Multicohort, Phase 2 Trial.

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Feb 1, 2029

Study completion Feb 26, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigated the efficacy and safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer.

Conditions

  • CRC (Colorectal Cancer)
  • BRAF

Interventions

  • Arm1Drug

    Tunlametinib + Cetuximab β Injection

  • Arm 2Drug

    Tunlametinib + Cetuximab β+Tislelizumab

  • Arm 3Drug

    Tunlametinib + BRAF inhibitor + Tislelizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.